跳至主要内容
临床试验/NCT02969174
NCT02969174Approved For Marketing不适用

Clinical Professor of Shanghai Tongji Hospital

Shanghai Tongji Hospital, Tongji University School of Medicine0 个研究点开始时间: 2016年11月21日最近更新:
适应症

试验速览

阶段
不适用
状态
Approved For Marketing
发起方

研究概览

简要总结

To establish a genotyping and extraction technology of non invasive prenatal diagnosis for fetal blood group genotype from cell-free fetal DNA in peripheral blood of pregnant women.

To achieve prenatal accurate identification of fetal blood group genotypes,and provide credible theoretical evidence for the prenatal diagnosis and treatment of hemolytic disease of newborn (HDN).

详细描述

Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

研究设计

研究类型
Expanded Access

入排标准

年龄范围
12 Weeks 至 38 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • blood samples of pregnant couples,gender/nation/region is unlimited.

排除标准

  • adipose or hemolytic samples,overdue samples,unidentified samples

研究者

发起方
Shanghai Tongji Hospital, Tongji University School of Medicine
申办方类型
Other
责任方
Principal Investigator
主要研究者

Liming Cheng

The President of Shanghai Tongji Hospital

Shanghai Tongji Hospital, Tongji University School of Medicine

相似试验